Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Bladder Cancer

4 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Treatment

VICCURO14100

03/24/2015

A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared with Chemotherapy in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer after Failure with Platinum-Containing Chemotherapy

Treatment

VICCMD1403

06/02/2014

An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

Treatment

VICCURO1382

02/10/2014

A Combined Phase 1 and Phase 2 Study of Albumin-bound Rapamycin Nanoparticles (nab-rapamycin, ABI-009) in the Treatment of BCG Refractory or Recurrent Nonmuscle Invasive Transitional Cell Bladder Cancer

Treatment

VICCMD1188

06/08/2012

An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers